Literature DB >> 17314274

Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer.

Archana Thakur1, Km Wahidur Rahman, Jack Wu, Aliccia Bollig, Hector Biliran, Xiukun Lin, Hind Nassar, David J Grignon, Fazlul H Sarkar, Joshua D Liao.   

Abstract

The consequence of activation status or gain/loss of an X-chromosome in terms of the expression of tumor suppressor genes or oncogenes in breast cancer has not been clearly addressed. In this study, we investigated the activation status of the X-chromosomes in a panel of human breast cancer cell lines, human breast carcinoma, and adjacent mammary tissues and a panel of murine mammary epithelial sublines ranging from low to high invasive potentials. Results show that most human breast cancer cell lines were homozygous, but both benign cell lines were heterozygous for highly polymorphic X-loci (IDS and G6PD). On the other hand, 60% of human breast carcinoma cases were heterozygous for either IDS or G6PD markers. Investigation of the activation status of heterozygous cell lines revealed the presence of only one active X-chromosome, whereas most heterozygous human breast carcinoma cases had two active X-chromosomes. Furthermore, we determined whether or not an additional active X-chromosome affects expression levels of tumor suppressor genes and oncogenes. Reverse transcription-PCR data show high expression of putative tumor suppressor genes Rsk4 and RbAp46 in 47% and 79% of breast carcinoma cases, respectively, whereas Cldn2 was down-regulated in 52% of breast cancer cases compared with normal adjacent tissues. Consistent with mRNA expression, immunostaining for these proteins also showed a similar pattern. In conclusion, our data suggest that high expression of RbAp46 is likely to have a role in the development or progression of human breast cancer. The activation status of the X-chromosome may influence the expression levels of X-linked oncogenes or tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314274     DOI: 10.1158/1541-7786.MCR-06-0071

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  35 in total

1.  Frequent epigenetic inactivation of RSK4 by promoter methylation in cancerous and non-cancerous tissues of breast cancer.

Authors:  Qiuyun Li; Yi Jiang; Wei Wei; Yinan Ji; Hui Gao; Jianlun Liu
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

2.  The enhancer of trithorax and polycomb gene Caf1/p55 is essential for cell survival and patterning in Drosophila development.

Authors:  Aimée E Anderson; Umesh C Karandikar; Kathryn L Pepple; Zhihong Chen; Andreas Bergmann; Graeme Mardon
Journal:  Development       Date:  2011-04-13       Impact factor: 6.868

3.  Intercellular transfer of proteins as identified by stable isotope labeling of amino acids in cell culture.

Authors:  Ming Li; Jason M Aliotta; John M Asara; Qian Wu; Mark S Dooner; Lynne D Tucker; Alan Wells; Peter J Quesenberry; Bharat Ramratnam
Journal:  J Biol Chem       Date:  2009-12-21       Impact factor: 5.157

4.  Rsk-mediated phosphorylation and 14-3-3ɛ binding of Apaf-1 suppresses cytochrome c-induced apoptosis.

Authors:  Jiyeon Kim; Amanda B Parrish; Manabu Kurokawa; Kenkyo Matsuura; Christopher D Freel; Joshua L Andersen; Carrie E Johnson; Sally Kornbluth
Journal:  EMBO J       Date:  2012-01-13       Impact factor: 11.598

Review 5.  Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases.

Authors:  Marie Cargnello; Philippe P Roux
Journal:  Microbiol Mol Biol Rev       Date:  2011-03       Impact factor: 11.056

6.  Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.

Authors:  Summer B Dewdney; B J Rimel; Premal H Thaker; Dominic M Thompson; Amy Schmidt; Phyllis Huettner; David G Mutch; Feng Gao; Paul J Goodfellow
Journal:  Clin Cancer Res       Date:  2011-03-03       Impact factor: 12.531

7.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

8.  Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.

Authors:  Fabian Arechavaleta-Velasco; Moises Zeferino-Toquero; Isaias Estrada-Moscoso; Fazlollah Shahram Imani-Razavi; Aleida Olivares; Carlos Eduardo Perez-Juarez; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2016-01-05       Impact factor: 3.064

9.  Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells.

Authors:  Archana Thakur; Yuan Sun; Aliccia Bollig; Jack Wu; Hector Biliran; Sanjeev Banerjee; Fazlul H Sarkar; D Joshua Liao
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  The role of retinoblastoma-associated proteins 46 and 48 in estrogen receptor alpha mediated gene expression.

Authors:  Amy L Creekmore; Kjirsten A Walt; Jennifer R Schultz-Norton; Yvonne S Ziegler; Ian X McLeod; John R Yates; Ann M Nardulli
Journal:  Mol Cell Endocrinol       Date:  2008-06-05       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.